Matthew Gavidia

Matthew is an associate editor for The American Journal of Managed Care® (AJMC®). He joined AJMC® in 2019 and creates content for Medical World News®, a 24-hour online program developed MJH Life Sciences® focusing on pressing topics within managed care, as well as the nonwork-related activities of health care stakeholders.

He has a BA in journalism & media studies and economics from Rutgers University. You can connect with Matthew on LinkedIn.


Dr Melissa O'Connor Reviews Considerations for Discharge in Home Health

September 30, 2022

Melissa O'Connor, PhD, MBA, RN, FGSA, FAAN, endowed professor in Community and Home Health Nursing, M. Louise Fitzpatrick School of Nursing, Villanova University, and director, Gerontology Interest Group, discussed several factors for clinicians to consider in creating plans to discharge adults from skilled home health care.

FDA Committee Issues Positive Vote for RBX2660 in Recurrent Clostridioides difficile Infection

September 28, 2022

An FDA advisory committee recently issued a positive vote for Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, for its potential in reducing recurrent Clostridioides difficile infection after antibiotic treatment.

Square-Stepping Exercise Linked With Improved Executive Functioning in Parkinson Disease

September 28, 2022

Adherence to 8-week square-stepping exercise training among patients with Parkinson disease was associated with significant improvement of executive functioning, as well as cognitive functioning for those with mild cognitive impairment.

Skin Biomarkers Found to Predict Development of Pediatric Atopic Dermatitis

September 26, 2022

Significant alterations were observed in lipid levels and other skin biomarkers for infants who developed atopic dermatitis (AD) vs controls, with phytosphingosine associated with the highest AD prediction accuracy.

Dr Jason Ezra Hawkes Discusses Clinical Considerations for Biologic Treatment in Atopic Dermatitis

September 24, 2022

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on the importance of shared decision-making in deciding which biologic would best alleviate disease burden in patients with moderate to severe atopic dermatitis.

Examining Biologic-Related Adverse Events in CRS With Nasal Polyps

September 23, 2022

Headaches, injection site reactions, and pharyngitis were the most common adverse events associated with the biologic therapies dupilumab, omalizumab, mepolizumab, and reslizumab in the treatment of chronic rhinosinusitis (CRS) with nasal polyps.